Ani Pharmaceutic (ANIP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANIP SEC filings page.
Ani Pharmaceutic (ANIP) reported $978.4M in revenue over the twelve months to Jun 30, 2026, up 30.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ANI’s dominant mechanic is profitable scale: revenue expansion now delivers cash conversion while leverage declines against a larger asset base.
In FY2025, cash conversion improved: operating cash flow was$185M versus$78M of net income, indicating earnings were not merely noncash. Free cash flow reached$171M against$14M of capital expenditures, so reported reinvestment absorbed only a small portion of operating cash.
The margin shape changed materially: operating margin reached
The financing posture became less debt-dependent: debt-to-equity fell to 0.5x in FY2025 from 0.8x in FY2024, showing equity grew faster than borrowings. Total assets reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ani Pharmaceutic's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ani Pharmaceutic has an operating margin of 12.6%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 45/100, indicating healthy but not exceptional operating efficiency. This is up from 0.1% the prior year.
Ani Pharmaceutic's revenue surged 43.8% year-over-year to $883.4M, reflecting rapid business expansion. This strong growth earns a score of 92/100.
Ani Pharmaceutic carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.71, Ani Pharmaceutic holds $2.71 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.
Ani Pharmaceutic converts 19.4% of revenue into free cash flow ($171.4M). This strong cash generation earns a score of 81/100.
Ani Pharmaceutic's ROE of 14.4% shows moderate profitability relative to equity, earning a score of 38/100. This is up from -4.7% the prior year.
Ani Pharmaceutic scores 2.32, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ani Pharmaceutic passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Ani Pharmaceutic generates $2.37 in operating cash flow ($185.2M OCF vs $78.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Ani Pharmaceutic earns $3.41 in operating income for every $1 of interest expense ($111.1M vs $32.6M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Ani Pharmaceutic generated $266.0M in revenue in Q2 2026. This represents an increase of 25.9% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
Ani Pharmaceutic's EBITDA was $60.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.7% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.
Ani Pharmaceutic reported $24.7M in net income in Q2 2026. This represents an increase of 189.1% from the same quarter a year earlier. Against the prior quarter it is down 16.2%.
Ani Pharmaceutic earned $1.05 per diluted share (EPS) in Q2 2026. This represents an increase of 191.7% from the same quarter a year earlier. Against the prior quarter it is down 18.0%.
Cash & Balance Sheet
Ani Pharmaceutic generated $53.6M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.
Ani Pharmaceutic held $360.2M in cash against $280.2M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Ani Pharmaceutic's gross margin was 62.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.
Ani Pharmaceutic's operating margin was 15.2% in Q2 2026, reflecting core business profitability. This is up 8.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.
Ani Pharmaceutic's net profit margin was 9.3% in Q2 2026, showing the share of revenue converted to profit. This is up 5.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.
Ani Pharmaceutic's ROE was 4.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Capital Allocation
Ani Pharmaceutic invested $14.7M in research and development in Q2 2026. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 39.1%.
Ani Pharmaceutic spent $813K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 47.5% from the same quarter a year earlier. Against the prior quarter it is down 95.9%.
Ani Pharmaceutic invested $3.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 23.9% from the same quarter a year earlier. Against the prior quarter it is down 49.7%.
ANIP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $266.0M+25.9% | $237.5M+20.5% | $247.1M+29.6% | $227.8M+53.6% | $211.4M+53.1% | $197.1M+43.4% | $190.6M+44.8% | $148.3M+12.5% |
| Cost of Revenue | $100.2M+34.2% | $93.6M+28.1% | $100.3M+24.9% | $93.4M+48.1% | $74.6M+29.3% | $73.0M+48.6% | $80.3M+50.3% | $63.1M+31.1% |
| Gross Profit | $165.9M+21.3% | $143.9M+16.0% | $146.8M+33.1% | $134.4M+57.7% | $136.8M+70.2% | $124.1M+40.6% | $110.3M+41.0% | $85.3M+1.8% |
| R&D Expenses | $14.7M-10.8% | $10.6M+0.3% | $12.3M-26.3% | $12.3M+21.5% | $16.5M+126.6% | $10.6M+0.5% | $16.6M+68.7% | $10.1M-8.9% |
| SG&A Expenses | $91.7M+12.1% | $73.7M-3.8% | $82.8M+18.7% | $76.7M-3.1% | $81.8M+54.8% | $76.5M+59.4% | $69.7M+56.8% | $79.1M+88.2% |
| Operating Income | $40.5M+191.2% | $38.9M+48.5% | $34.8M+894.1% | $36.2M+276.6% | $13.9M+168.8% | $26.2M+29.0% | -$4.4M-165.1% | -$20.5M-214.3% |
| EBITDA | $60.1M+61.7% | $59.8M+21.8% | $57.4M+214.9% | $58.9M+1334.0% | $37.2M+87.1% | $49.1M+40.3% | $18.2M-16.9% | -$4.8M-114.4% |
| Interest Expense | $7.5M-8.8% | $7.6M-6.8% | $8.0M-9.6% | $8.3M+24.3% | $8.2M-9.3% | $8.1M-10.9% | $8.8M-23.3% | $6.7M-19.9% |
| Income Tax | $12.4M+526.8% | $10.7M+149.2% | $4.0M+214.4% | $7.2M+198.0% | $2.0M | $4.3M-39.6% | -$3.5M-1576.0% | -$7.3M-566.7% |
| Net Income | $24.7M+189.1% | $29.5M+88.1% | $27.2M+352.5% | $26.6M+210.1% | $8.5M+473.8% | $15.7M-13.9% | -$10.8M-881.5% | -$24.2M-343.1% |
| EPS (Basic) | $1.09+194.6% | $1.31+87.1% | $1.24+325.5% | $1.19+193.7% | $0.37+364.3% | $0.70-16.7% | -$0.55-2850.0% | -$1.27-376.1% |
| EPS (Diluted) | $1.05+191.7% | $1.28+85.5% | $1.17+312.7% | $1.13+189.0% | $0.36+357.1% | $0.69-15.9% | -$0.55 | -$1.27-382.2% |
| Diluted Shares (Avg) | 22M+7.9% | 22M+7.5% | N/A | 21M+8.7% | 20M+5.1% | 20M+3.2% | N/A | 19M+1.5% |
ANIP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+11.3% | $1.4B+10.0% | $1.4B+12.1% | $1.4B+9.4% | $1.3B+45.9% | $1.3B+41.3% | $1.3B+42.0% | $1.3B+44.7% |
| Current Assets | $825.4M+37.0% | $747.1M+39.3% | $753.1M+42.5% | $698.4M+34.0% | $602.6M+8.5% | $536.3M-0.8% | $528.5M+1.7% | $521.3M+4.8% |
| Cash & Equivalents | $360.2M+65.4% | $311.2M+107.7% | $285.6M+97.1% | $262.6M+81.1% | $217.8M-9.3% | $149.8M-34.5% | $144.9M-34.5% | $145.0M-24.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $143.1M+3.5% | $143.5M+4.4% | $143.1M+4.6% | $146.5M-1.1% | $138.3M+10.3% | $137.4M+20.7% | $136.8M+23.0% | $148.0M+38.9% |
| Accounts Receivable | $274.5M+21.6% | $255.4M+15.9% | $281.1M+26.8% | $252.6M+28.6% | $225.7M+35.9% | $220.3M+27.8% | $221.7M+36.8% | $196.4M+9.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $62.5M+3.2% | $62.5M+3.0% | $62.5M+4.2% | $62.5M+3.4% | $60.5M+114.5% | $60.7M+115.0% | $60.0M+112.6% | $60.4M+114.1% |
| Total Liabilities | $896.9M+1.8% | $859.7M+1.3% | $899.7M+5.1% | $902.3M+5.3% | $881.4M+100.3% | $849.0M+94.0% | $855.9M+91.6% | $856.6M+96.8% |
| Current Liabilities | $283.7M+19.8% | $239.5M+18.7% | $278.1M+43.0% | $270.6M+42.4% | $236.8M+69.2% | $201.8M+47.4% | $194.5M+33.7% | $189.9M+41.4% |
| Non-Current Liabilities | $613.2M-4.9% | $620.2M-4.2% | $621.5M-6.0% | $631.8M-5.2% | $644.6M+114.7% | $647.1M+115.1% | $661.5M+119.5% | $666.6M+121.6% |
| Long-Term Debt | $280.2M-7.1% | $286.0M-6.3% | $291.8M-5.6% | $297.7M-4.9% | $301.5M+6.0% | $305.3M+7.3% | $309.1M+8.5% | $312.9M+9.8% |
| Total Equity | $597.2M+36.7% | $562.3M+34.3% | $540.7M+33.9% | $505.8M+24.6% | $436.8M-4.2% | $418.6M-7.4% | $403.7M-6.7% | $405.9M-5.6% |
| Retained Earnings | $31.1M+140.5% | $6.4M+107.5% | -$23.1M+77.0% | -$50.6M+43.5% | -$76.9M-18.2% | -$85.0M-36.4% | -$100.3M-25.1% | -$89.6M-10.8% |
ANIP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $56.7M-25.3% | $58.4M+66.8% | $30.4M+91.5% | $44.1M+253.2% | $75.8M+335.4% | $35.0M+91.5% | $15.9M-64.6% | $12.5M-61.2% |
| Depreciation & Amortization | $19.6M-15.6% | $20.9M-8.6% | $22.6M+0.1% | $22.6M+43.7% | $23.3M+58.4% | $22.9M+55.9% | $22.6M+48.7% | $15.7M+3.6% |
| Stock-Based Compensation | N/A | $10.2M+14.9% | N/A | N/A | N/A | $8.9M+27.9% | N/A | N/A |
| Capital Expenditures | $3.1M-23.9% | $6.1M+145.5% | $1.2M-48.0% | $6.1M+26.8% | $4.0M-9.8% | $2.5M-46.0% | $2.4M+5.0% | $4.8M+176.7% |
| Free Cash Flow | $53.6M-25.3% | $52.3M+60.8% | $29.1M+116.3% | $38.0M+395.3% | $71.8M+453.8% | $32.5M+137.6% | $13.5M-68.3% | $7.7M-74.8% |
| Investing Cash Flow | -$3.1M+55.8% | -$11.3M+42.9% | -$1.4M+86.9% | -$6.2M+98.5% | -$6.9M-55.3% | -$19.8M-322.2% | -$10.7M-123.5% | -$398.5M-8653.0% |
| Financing Cash Flow | -$4.6M-166.0% | -$21.6M-118.2% | -$4.6M+5.5% | $6.3M-97.8% | -$1.7M-20.3% | -$9.9M+49.8% | -$4.9M+58.8% | $291.0M+7650.5% |
| Dividends Paid | $0-100.0% | $0-100.0% | $0-100.0% | $344K-15.3% | $407K0.0% | $406K0.0% | $406K0.0% | $406K0.0% |
| Share Buybacks | $813K+47.5% | $19.8M+97.5% | $611K+92.1% | $1.0M+53.5% | $551K-57.6% | $10.0M+15.5% | $318K+37.7% | $680K+1.5% |
ANIP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.4%-2.3pp | 60.6%-2.4pp | 59.4%+1.5pp | 59.0%+1.5pp | 64.7%+6.5pp | 62.9%-1.3pp | 57.9%-1.5pp | 57.5%-6.0pp |
| Operating Margin | 15.2%+8.6pp | 16.4%+3.1pp | 14.1%+16.4pp | 15.9%+29.7pp | 6.6%+2.8pp | 13.3%-1.5pp | -2.3%-7.4pp | -13.8%-27.4pp |
| Net Margin | 9.3%+5.3pp | 12.4%+4.5pp | 11.0%+16.6pp | 11.7%+28.0pp | 4.0%+5.7pp | 8.0%-5.3pp | -5.6%-6.7pp | -16.3%-23.8pp |
| Return on Equity | 4.1%+2.2pp | 5.2%+1.5pp | 5.0%+7.7pp | 5.3%+11.2pp | 2.0%+2.5pp | 3.8%-0.3pp | -2.7%-3.0pp | -5.9%-8.3pp |
| Return on Assets | 1.7%+1.0pp | 2.1%+0.9pp | 1.9%+2.7pp | 1.9%+3.8pp | 0.6%+0.9pp | 1.2%-0.8pp | -0.8%-1.0pp | -1.9%-3.0pp |
| Current Ratio | 2.91+0.4x | 3.12+0.5x | 2.710.0x | 2.58-0.2x | 2.54-1.4x | 2.66-1.3x | 2.72-0.9x | 2.74-1.0x |
| Debt-to-Equity | 0.47-0.2x | 0.51-0.2x | 0.54-0.2x | 0.59-0.2x | 0.69+0.1x | 0.73+0.1x | 0.77+0.1x | 0.77+0.1x |
| Asset Turnover | 0.180.0x | 0.170.0x | 0.170.0x | 0.160.0x | 0.160.0x | 0.150.0x | 0.150.0x | 0.120.0x |
| FCF Margin | 20.2%-13.8pp | 22.0%+5.5pp | 11.8%+4.7pp | 16.7%+11.5pp | 34.0%+24.6pp | 16.5%+6.5pp | 7.1%-25.2pp | 5.2%-17.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ani Pharmaceutic ANIP | FY2025 | $883.4M | $78.0M | 8.8% | $1.6B | 69/100 |
| Alvotech ALVO | FY2025 | $586.3M | $27.9M | 4.8% | $1.9B | 26/100 |
| Indivior Pharmaceuticals Inc. INDV | FY2025 | $1.2B | $210.0M | 17.0% | $4.1B | 44/100 |
| Supernus Pharma SUPN | FY2025 | $719.0M | -$38.6M | -5.4% | $2.5B | 53/100 |
| Amneal Pharmaceuticals Inc AMRX | FY2025 | $3.0B | $72.1M | 2.4% | $6.1B | 56/100 |
| Hutchmed (China) Limited HCM | FY2025 | $548.5M | $456.9M | 83.3% | $2.4B | 42/100 |
Where Ani Pharmaceutic Ranks
Frequently Asked Questions
What is Ani Pharmaceutic's annual revenue?
Ani Pharmaceutic (ANIP) reported $883.4M in total revenue for fiscal year 2025. This represents a 43.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ani Pharmaceutic's revenue growing?
Ani Pharmaceutic (ANIP) revenue grew by 43.8% year-over-year, from $614.4M to $883.4M in fiscal year 2025.
Is Ani Pharmaceutic profitable?
Yes, Ani Pharmaceutic (ANIP) reported a net income of $78.0M in fiscal year 2025, with a net profit margin of 8.8%.
What is Ani Pharmaceutic's EBITDA?
Ani Pharmaceutic (ANIP) had EBITDA of $202.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ani Pharmaceutic have?
As of fiscal year 2025, Ani Pharmaceutic (ANIP) had $285.6M in cash and equivalents against $291.8M in long-term debt.
What is Ani Pharmaceutic's gross margin?
Ani Pharmaceutic (ANIP) had a gross margin of 61.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ani Pharmaceutic's operating margin?
Ani Pharmaceutic (ANIP) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ani Pharmaceutic's net profit margin?
Ani Pharmaceutic (ANIP) had a net profit margin of 8.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ani Pharmaceutic's return on equity (ROE)?
Ani Pharmaceutic (ANIP) has a return on equity of 14.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ani Pharmaceutic's free cash flow?
Ani Pharmaceutic (ANIP) generated $171.4M in free cash flow during fiscal year 2025. This represents a 258.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ani Pharmaceutic's operating cash flow?
Ani Pharmaceutic (ANIP) generated $185.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ani Pharmaceutic's total assets?
Ani Pharmaceutic (ANIP) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ani Pharmaceutic's capital expenditures?
Ani Pharmaceutic (ANIP) invested $13.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ani Pharmaceutic spend on research and development?
Ani Pharmaceutic (ANIP) invested $51.7M in research and development during fiscal year 2025.
What is Ani Pharmaceutic's current ratio?
Ani Pharmaceutic (ANIP) had a current ratio of 2.71 as of fiscal year 2025, which is generally considered healthy.
What is Ani Pharmaceutic's debt-to-equity ratio?
Ani Pharmaceutic (ANIP) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ani Pharmaceutic's return on assets (ROA)?
Ani Pharmaceutic (ANIP) had a return on assets of 5.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ani Pharmaceutic's P/E ratio?
Ani Pharmaceutic (ANIP) trades at 14.9x earnings, its market capitalization divided by net income of $108.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.6B as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ani Pharmaceutic's price-to-sales ratio?
Ani Pharmaceutic (ANIP) trades at 1.6x sales, its market capitalization divided by revenue of $978.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.6B as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ani Pharmaceutic's Altman Z-Score?
Ani Pharmaceutic (ANIP) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ani Pharmaceutic's Piotroski F-Score?
Ani Pharmaceutic (ANIP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ani Pharmaceutic's earnings high quality?
Ani Pharmaceutic (ANIP) has an earnings quality ratio of 2.37x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ani Pharmaceutic cover its interest payments?
Ani Pharmaceutic (ANIP) has an interest coverage ratio of 3.41x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ani Pharmaceutic?
Ani Pharmaceutic (ANIP) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.